Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Condition(s):Locally Advanced or Metastatic Breast CancerLast Updated:April 11, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Locally Advanced or Metastatic Breast CancerLast Updated:April 11, 2023Active, not recruiting
Condition(s):Advanced Breast CancerLast Updated:June 3, 2021Unknown status
Condition(s):HER2-positive Metastatic Breast CancerLast Updated:July 17, 2023Terminated
Condition(s):Metastatic Breast CancerLast Updated:February 1, 2013Completed
Condition(s):Advanced Breast CancerLast Updated:November 17, 2010Completed
Condition(s):Estrogen Receptor Status; HER2/Neu Negative; Invasive Breast Carcinoma; Postmenopausal; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast CancerLast Updated:January 18, 2024Active, not recruiting
Condition(s):PharmacokineticsLast Updated:June 3, 2021Completed
Condition(s):Locally Advanced or; Metastatic Breast CancerLast Updated:September 5, 2021Completed
Condition(s):Breast CancerLast Updated:January 28, 2021Terminated
Condition(s):Metastatic Breast CancerLast Updated:July 23, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.